

H.O: 203/4 SAHAKAR BHAVAN, 340/48 N.N STREET, MUMBAI-400009 ☎ : (022) 23455543 Email: corporate@aareydrugs.com
REGD OFF. & FACTORY: E-34 MIDC, TARAPUR, BOISAR, DIST.-THANE ☎ (02525) 271049 Email: info@aareydrugs.com
CIN: L99999MH1990PLC056538

Date:- 12th April, 2023

To,

BSE Limited The Manager, Corporate Service Department P.J. Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 524412	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: AAREYDRUGS
--	---

Subject: Certificate under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the year ended 31st March, 2023.

Dear Sir/Madam,

Please find enclosed herewith Certificate under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the year ended 31st March, 2023.

Please take on record of the same and oblige

Thanking You,

Yours faithfully,

For Aarey Drugs & Pharmaceuticals Limited

Lalit
Radhakrishna
Tulsiani
Lalit Tulsiani
Director
DIN: 01652630

Digitally signed by Lalit Radhakrishna Tulsiani
DN: c=IN, st=Maharashtra,
2.5.4.20=bdad8e726231db3b0414860f5abb4b795f2a11e
c7681e5f4bd0f15a0b4fa5e, postalCode=400053,
street=Behind JVPO Bus Depot, Andheri West, Mumbai,
pseudonym=d41d8cd98f00b204e9800998ecf8427e,
serialNumber=a3776d63863c4f5c25029d9919a6d71e47
5aef66483ca15ab02c9f825c4, o=Personal, cn=Lalit
Radhakrishna Tulsiani
Date: 2023.04.12 12:12:26 +05'30'

Encl.: a/a

Virendra Bhatt

Company Secretary

Office :

Office No.: 03, A Wing, 9th Floor,

Pinnacle Corporate Park,

BKC CST Link Rd., MMRDA Area,

Bandra Kurla Complex,

Bandra East, Mumbai - 400 051

Tel.: 022 - 2652 9367 / 68

Mobile No.: +91 98200 48670

Email : bhattvirendra1945@yahoo.co.in

Name of the Company : Aarey Drugs and Pharmaceuticals Limited

CIN : L99999MH1990PLC056538

Registered Office : E-34, M.I.D.C., Tarapur, Boisar, Thane - 401506,
Maharashtra, India.

CERTIFICATE UNDER REGULATION 40(9) OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2023

The Securities and Exchange Board of India (SEBI) vide gazette notification dated 08th June, 2018 and vide its press release dated 03rd December, 2018 ("SEBI's operational guidelines"), amended Regulation 40 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and had mandated transfer of securities only in dematerialized form w.e.f. 01st April, 2019.

Further, the SEBI vide gazette notification dated 24th January, 2022 read with SEBI circular No.: SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated 25th January, 2022 ("SEBI's operational guidelines") had mandated issuance of certificates or receipts or advices, as applicable in dematerialized form only, while processing the service requests relating to Issue of duplicate securities certificate, Claim from Unclaimed Suspense Account, Renewal / Exchange of securities certificate, Endorsement, Subdivision/Splitting of securities certificate, Consolidation of securities certificates / folios, Transmission and Transposition.

Accordingly, I have examined all the relevant documents relating to **Aarey Drugs and Pharmaceuticals Limited** maintained by **Link Intime India Private Limited ("RTA")** for the purpose of issuing the Certificate as per Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the period from **01st April, 2022 to 31st March, 2023** and based on the information provided, I hereby certify that:



✓

A. As informed to me, the RTA has not processed any physical transfer, transmission, transposition of securities, renewal, consolidation, exchange, issue of duplicate securities certificate, deletion of name and sub-division (split) etc. as per SEBI's operational guidelines.

V. G. Bhatt


Date: 12th April, 2023

Place: Mumbai

Virendra G. Bhatt

Practicing Company Secretary

ACS No.: 1157 / COP No.: 124

Peer Review Cert. No.: 1439/2021

UDIN: A001157E000066453